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LETTERS TO THE EDITOR
IgG Anti-LABD97 Antibodies in Bullous Pemphigoid
Patients' Sera React with the Mid-Portion of the BPAg2
Ectodomain
To the Editor
The 180 kDa bullous pemphigoid antigen, BPAg2, is a transmem-
brane protein that is important in basement membrane cohesion.
Circulating antibodies in bullous pemphigoid (BP) patients' sera
have been shown to target epitopes that are tightly clustered in the
sixteenth noncollagenous domain (NC16A) of the extracellular
portion BPAg2 (Zillikens et al, 1997). We have previously shown
that some BP patients' sera contain IgG antibodies reactive with the
LABD97 antigen which is structurally identical to a portion of the
extracellular domain of BPAg2 (Zone et al, 1998; Egan et al, 1999).
These IgG anti-LABD97 antibodies cross-reacted with BPAg2 but
did not recognize epitopes in its NC16A domain. In this study,
af®nity-puri®ed IgG anti-LABD97 antibodies from bullous pem-
phigoid patients' sera were reacted with three protein constructs
that together encode almost the entire extracellular domain of
BPAg2.
Construct EC2 (amino acids 527±1187) in pCEP-Pu vector was
obtained from Dr. Peter Mueller, University of Lubeck, Germany
(Areida et al, 1999). Another BPAg2 ectodomain construct, EC3
coding for amino acids 482±616, was generated using the sense
primer 5¢-GCTCTTCGGCCTCATTGCTCT-3¢ and the anti-
sense primer 5¢-CATGCCAGGATCTCCCACGCT-3¢. The Nhe
I-Not I digested PCR product was cloned into a modi®ed pCEP-
Pu vector that additionally coded for an eight amino acid FLAG
peptide that preceded the APLA residues in frame, thereby
resulting in a FLAG-tagged EC3 polypeptide. The resulting
peptide migrated with a molecular weight of approximately
30 kDa.
These two ectodomain constructs were expressed using the HEK
293 EBNA mammalian expression system and selected using 5 mg
per ml of the antibiotic puromycin (Sigma, St. Louis, MO). The
EC3 protein was puri®ed from conditioned media using an anti-
FLAG af®nity column (Sigma, St. Louis, MO), while the EC2
protein was obtained by concentrating conditioned media using a
Centricon ®lter (Amicon, Beverly, MA) and then used for western
blotting.
GST-BP-915, a GST fusion protein, contains 305 amino acids
(1193±1497) of the distal region of the BPAg2 extracellular domain
as reported previously (Nie and Hashimoto, 1999). To produce this
recombinant protein, an appropriate cDNA fragment of BPAg2
was obtained by PCR of a KU8 cDNA library and put into a
pGST-2T vector for its production. To decrease the degradation of
the protein, BL12 was used as the host bacteria and the culture
temperature was adjusted to 14°C. The fusion protein was induced
by IPTG and puri®ed from bacterial lysates by a glutathione-
agarose af®nity column.
IgG antibodies speci®c for the LABD97 antigen were af®nity
puri®ed from sera by elution of antibodies from LABD97 bound to
nitrocellulose strips as described by Olmsted (1981) and modi®ed
by Smith and Fisher (1984). Protein in sample buffer was applied to
a 10% polyacrylamide gel, and sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis was performed (Laemmli, 1970). Proteins
were transferred electrophoretically onto nitrocellulose, and the
nitrocellulose strips were incubated with sera or eluates for 2 h at
room temperature (Towbin et al, 1979). Immunoblots were
developed using a biotin labeled antihuman g-chain antibody and
an avidin-biotin-peroxidase complex. Reaction times for all lanes
of individual blots were identical.
In this study, 12 BP patients' sera were used (Fig 1). All had a
circulating IgG antibody titer of at least 40 binding to the epidermal
side of 1 M NaCl split skin on indirect immuno¯uorescence
microscopy. Antibody eluates from nine of these BP sera contained
IgG anti-LABD97 speci®c antibodies, all of which reacted with the
EC2 construct containing 660 amino acids from the mid-portion of
the BPAg2 ectodomain. Eluates from three patients' sera with IgG
antibodies reactive with BPAg2 but not LABD97 on western blot,
or eluates from negative control sera, subjected to identical af®nity
puri®cation procedures, did not react with this construct. Only one
patient's af®nity-puri®ed IgG anti-LABD97 antibodies reacted
with the EC3 construct containing 134 amino acids (including the
entire NC16A domain and parts of the transmembrane region and
part of the ®fteenth collagenous domain). Eluates from all 12
af®nity-puri®ed BP patient's sera failed to react with the GST-BP-
915 bacterial fusion protein containing the carboxy-terminal 304
amino acids of BPAG2.
This study demonstrates that BP patients' sera that contain IgG
antibodies reactive with LABD97 react with an epitope or epitopes
contained in a 571 amino acid stretch of the mid-portion of the
BPAg2 ectodomain. It con®rms the ®ndings of our previous study
by showing that nearly all of the af®nity-puri®ed IgG anti-LABD97
speci®c antibodies fail to react with the NC16A domain of BPAg2
(Egan et al, 1999). One patient's af®nity-puri®ed anti-LABD97
antibodies did react with the EC3 construct. We postulate that
these antibodies reacted either with a post-translationally modi®ed
epitope not contained in the bacterial fusion protein used
previously, or that they recognized an epitope contained in the
amino-terminal region of the ®fteenth collagenous domain.
It is not surprising that none of the patients' af®nity-puri®ed
antibodies reacted with the bacterial fusion protein containing the
carboxy-terminal region of BPAg2. When LABD97 was partially
sequenced, no homologous amino acid sequences were detected in
the carboxy-terminal 237 amino acids of BPAg2, suggesting that
the carboxy-terminus of LABD97 lies in this region of BPAg2
(Zone et al, 1998). Therefore, any antibodies in the test patients'
sera reactive with epitopes in this region of BPAg2 would not bind
to LABD97 and thus would not be af®nity puri®ed.
The fact that the IgG anti-LABD97 antibodies cross-react with
BPAg2 is notable. IgA antibodies targeting LABD97 do not cross-
react with BPAg2 (Zone et al, 1990; Dmochowski et al, 1993).
Therefore, it seems likely that both antibody isotypes recognize
different epitopes on LABD97. The ®nding of antibodies targeting
epitopes other than the NC16A domain of BPAg2 in BP patients'
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sera is well documented (Perriard et al, 1999; Egan et al, 1999;
Schumann et al 2000). This may just represent the phenomenon of
epitope spreading (Chan et al, 1998). The pathogenic relevance of
these IgG antibodies to LABD97 in BP is unknown, however. In a
mouse model of BP, using rabbit IgG anti-BPAg2 antibodies, Liu
et al (1995) have demonstrated that pathogenic antimurine BPAg2
antibodies bind to a site within the murine NC14A domain, which
is equivalent to the NC16A domain of human BPAg2. These
antibodies bind to neonatal mouse skin basement membrane and
induce complement activation leading to an in¯ammatory in®ltrate
with neutrophils leading to subepidermal separation with rapid
sloughing of epidermis. We are currently developing an animal
model of BP using human skin engrafted immunode®cient mice.
Preliminary results suggest that passive transfer of mouse IgG class
monoclonal antibodies to LABD97 induces subepidermal graft
separation with an in¯ammatory in®ltrate of eosinophils, mirroring
the disease process in humans.1 This suggests that antibodies to the
LABD97 antigen region of BPAg2 (i.e., antibodies targeting
epitopes outside the NC16A domain) may be important in the
pathogenesis of BP.
In summary, we have characterized the binding speci®city of
anti-LABD97 IgG class antibodies in BP patients' sera and
demonstrated that they selectively bind to a region in the mid-
portion of the BPAg2 ectodomain that is potentially different from
the epitope recognized by IgA antibodies in linear IgA bullous
dermatosis. Moreover, this region is distinct from antibody reactive
sites previously described on the BPAg2 ectodomain in BP patients'
sera.
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Figure 1. Af®nity-puri®ed IgG anti-LABD97 antibodies from BP patients' sera recognize the mid-portion of the BPAg2 ectodomain. The
top panels are immunoblots using BP patient sera that were immunoaf®nity puri®ed using the LABD97 antigen. In each case western blots were performed
using the recombinant constructs illustrated in the lower panel. The order of BP patients' af®nity-puri®ed IgG antibodies is the same in all three blots (lanes
1±12). (EC3) Western immunoblot showing reactivity of LABD97 af®nity-puri®ed IgG antibodies from one patient's serum with construct EC3 (lane 9).
Af®nity-puri®ed negative control sera (lanes 13, 14) demonstrated no reactivity with this construct. Two BP patients' sera, known to contain antibodies to
the NC16A domain, reacted with the construct (lanes 15, 16). (EC2) Western immunoblot showing reactivity of LABD97 af®nity-puri®ed IgG antibodies
from nine BP patients' sera reacting with construct EC2 (lanes 1±9). Eluates from three BP patients' sera with IgG antibodies reactive with BPAg2 but not to
LABD97, did not react with this construct (lanes 10±12). Af®nity-puri®ed negative control sera (lanes 15, 16) and a lane with no primary antibody (lane 13)
demonstrated no reactivity with this construct. A positive control rabbit antibody speci®c for BPAg2 reacted with the construct (lane 14). (915) Western
immunoblot showing no reactivity of any af®nity-puri®ed IgG antibodies with bacterial fusion protein GST-BP-915 from BP sera (lanes 1±12) or from
negative control sera (lanes 13, 14). Two cicatricial pemphigoid patients' sera known to react with this fusion protein were used as positive controls (lanes 15,
16). (Lower panel) Diagram showing the structure of BPAg2. The amino-terminus of LABD97 is illustrated. The three protein constructs are outlined above
the corresponding part of the BPAg2 ectodomain that they represent. Arrows point from each construct to its western immunoblot with the af®nity-puri®ed
IgG antibodies to LABD97.
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FcRg Represents the Fc Receptor g Chain Whereas FcgR
Means the Fc Receptor for IgG
To the Editor:
We read with great interest the article titled ``Chemical activation
of innate and speci®c immunity in contact dermatitis'' in the recent
issue of the Journal of Investigative Dermatology (Zhang and Tinkle,
2000).
The cell surface receptors for the Fc portion of immunoglobulins
are termed as Fc receptors (FcR). FcR are de®ned by their
speci®city for immunoglobulin isotypes. Fc receptors for IgG are
referred as FcgR, for IgE as FceR, for IgA as FcaR, for IgM as
FcmR, etc. (Kinet, 1989; Ravetch and Kinet, 1991).
It has been demonstrated that some FcR are multimeric
complexes and share identical subunits. The high-af®nity FceR
(FceRI) is composed of one a chain (FceRIa), one b chain
(FceRIb), and two g chains (FceRIg). The low-af®nity FcgR
(FcgRIII) shares the indentical g chain with FceRI (Wang et al,
1992; Kinet, 1999). Loss of the g chain results in the loss of FceRI
and FcgRIII expression on cells where those receptors are normally
present. Targeted disruption of the g chain results in immuno-
compromised mice. The innate immunity is impaired in such mice.
Defects in the natural killer cell-mediated antibody-dependent
cytotoxicity (ADCC) and mast cell-mediated allergic responses are
evident in mutant mice de®cient in FcR g chain (FcRgnl) (Takai
et al, 1994).
Zhang and Tinkle investigated the effect of de®ciency in FcR g
chain on oxazolone-induced contact hypersensitivity and irritant
responses in mice. Such studies are very interesting; however, the
authors employed the abbreviation FcgR for the FcR g subunit,
and thus FcgR KO mice represented FcR g chain KO mice. This
leads to a misunderstanding. Actually, FcgR KO mice should
represent KO mice de®cient in Fc receptor for IgG rather than
de®cient in FcR g chain. Therefore, we would suggest that FcRg,
rather than FcgR, KO mice should be used for the gene-targeted
mutant mice de®cient in Fc receptor g chain.
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